Quetiapine (Seroquel) FDA Indications for Bipolar Disorder
Quetiapine is FDA-approved for BOTH bipolar mania and bipolar depression, making it one of the most versatile agents in bipolar disorder treatment. 1
FDA-Approved Indications
According to the FDA drug label, quetiapine has the following specific approvals 1:
For Acute Mania:
- Monotherapy for acute manic episodes in bipolar I disorder (adults and children/adolescents 10-17 years)
- Adjunctive therapy to lithium or divalproex for acute manic episodes (adults)
For Acute Depression:
- Monotherapy for acute depressive episodes associated with bipolar disorder (adults with bipolar I or II disorder) 1
For Maintenance Treatment:
- Adjunctive therapy to lithium or divalproex for maintenance treatment of bipolar I disorder (adults) 1
Clinical Evidence Supporting Both Indications
The FDA approval is based on robust clinical trial data 1:
For Bipolar Depression:
- Two 8-week placebo-controlled trials (BOLDER I and II) demonstrated efficacy at both 300 mg/day and 600 mg/day doses
- Statistically significant improvement in MADRS scores compared to placebo (placebo-subtracted differences of 4.1-6.5 points)
- Improvement seen as early as Day 8 (week 1)
- Effective for both bipolar I and bipolar II depression 1
For Bipolar Mania:
- Multiple 12-week monotherapy trials in adults and 3-week trials in pediatric patients established efficacy
- Dosing range: 400-800 mg/day 1
For Maintenance:
- Two large placebo-controlled trials (n=1326) showed quetiapine plus lithium or divalproex significantly increased time to recurrence of any mood event (manic, mixed, or depressed episodes)
- Treatment effect was present for preventing both manic AND depressed episodes 1
Clinical Context and Unique Position
Quetiapine is the only atypical antipsychotic approved as monotherapy for bipolar depression 2, 3. This distinguishes it from other second-generation antipsychotics that only have approval for mania. The olanzapine-fluoxetine combination is the only other FDA-approved treatment specifically for bipolar depression, but it requires combination therapy 4.
Dosing Specifics:
For Bipolar Depression:
- 300 mg/day or 600 mg/day (no additional benefit seen with 600 mg dose)
- Given once daily at bedtime 5
For Bipolar Mania:
- 400-800 mg/day in divided doses
- Rapid titration over 4 days to 400 mg/day 1
Important Clinical Considerations
Advantages:
- Broad mood-stabilizing properties across all phases of bipolar disorder 2, 3
- Low risk of treatment-emergent affective switch (no increased risk of switching into mania during depression treatment) 5
- Low incidence of extrapyramidal symptoms 6
Tolerability Profile:
- Number needed to harm (NNH) for somnolence = 3, dry mouth = 4 7
- NNH for ≥7% weight gain = 16 7
- More favorable metabolic profile compared to olanzapine-fluoxetine combination but less favorable than lurasidone 7
Guideline Context:
While the provided guidelines [4-4] are from 2007 and list quetiapine as approved for acute mania in adults, the current FDA label 1 reflects expanded indications that now include bipolar depression and maintenance therapy. The 2007 guidelines note that quetiapine was among several atypical antipsychotics approved for acute mania 4, but the depression indication came after these guidelines were published.